[1] 1.Patel JG,Nagar SP,Dalal AA.Indirect costs in chronic obstructive pulmonary disease:a review of the economic burden on employers and individuals in the United States[J].Int J Chron Obstruct Pulmon Dis,2014,19(9):289-300.
[2] Hillas G,Perlikos F,Tzanakis N.Acute exacerbation of COPD:is it the "stroke of the lungs"[J]?Int J Chron Obstruct Pulmon Dis,2016 ,13(11):1579-1586.
[3] Vogelmeier CF,Criner GJ,Martinez FJ,et al.Global strategy for the diagnosis,management and prevention of chronic obstructive lung disease 2017 report:GOLD executive summary[J].Respirology,2017 ,22(3):575-601.
[4] Connors AF,Dawson NV,Thomas C,et al.Outcomes following acute exacerbation of severe chronic obstructive lung disease.The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) [J].Am J Respir Crit Care,1996,154(4):959-967.
[5] Gunen H,Hacievliyagil SS,Kosar F,et al.Factors affecting survival of hospitalised patients with COPD[J].Eur Respir J,2005,26(2):234-241.
[6] Debrus C,Bonhomme O,Corhay JL.Reducing COPD exacerbations:a challenge in 2017[J].Rev Med Liege,2017,72(2):74-80.
[7] Halpin DM.Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT trial[J].Lung,2011,189(4):261-268.
[8] Winter MP,Blessberger H,Alimohammadi A,et al.Long-term outcome and risk assessment in premature acute myocardial infarction:A 10-year follow-up study[J].Int J Cardiol,2017 ,240(1):37-42.
[9] Fuhrman C,Moutengou E,Roche N,et al.Prognostic factors after hospitalization for COPD exacerbation[J].Rev Mal Respir,2017 ,34(1):1-18.
[10] García-Sanz MT,Cánive-Gómez JC,García-Couceiro N,et al.Factors associated with the incidence of serious adverse events in patients admitted with COPD acute exacerbation[J].Ir J Med Sci,2016 ,186(2):477-483.
[11] Meier MA,Ottiger M,Vgeli A,et al.Activation of the serotonin pathway is associated with poor outcome in COPD exacerbation:results of a long-term cohort study[J].Lung,2017,195(3):303-311.
[12] Calverley PM,Anderson JA,Celli B,et al.Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease[J].N Engl J Med,2007,356(8):775-789.[13] Tashkin DP,Celli B,Senn S,et al.A 4-year trial of tiotropium in chronic obstructive pulmonary disease[J].N Engl J Med,2008,359(9):1543-1554.[14] Hurst JR,Vestbo J,Anzueto A,et al.Susceptibility to exacerbation in chronic obstructive pulmonary disease[J].N Engl J Med,2010,363(12):1128-1138.[15] Goudis CA.Chronic obstructive pulmonary disease and atrial fibrillation:An unknown relationship[J].J Cardiol,2017,69(5):699-705.
[16] 韩振军.AECOPD住院病人合并症状况调查[J].临床肺科杂志,2008,13(6):705-706.
[17] Zhu JJ,Liu LJ.Analysis of factors influenced by the effectiveness of non-invasive ventilation in the treatment of acute exacerbation of chronic obstructive pulmonary disease with different severities[J].Eur Rev Med Pharmacol Sci,2016 ,20(22):4775-4781. |
2018, Vol. 35 
